transepidermal water loss, since vasoconstriction assay does not test application site reactions.
For all of these reasons, I am worried about my patients’ well-being every time I write
a generic topical corticosteroid prescription.
However, we now have branded generics in which the manufacturers have begun producing
their own authorized generics with the exact same excipients as in their original branded
vehicles. Promius Pharma, one of the leaders in this field, recently brought to the market
clocortolone pivalate 0.1% generic formulation, which is exactly the same as their original
branded product. Another advantage is that this formulation is the only authorized generic
formulation of clocortolone pivalate 0.1% cream on the market.2
The new trend of authorized exact same generics of unique products such as clocortolone pivalate
0.1% is a welcome addition to our treatment armamentarium and a great service to our patients,
allowing me to prescribe this generic formulation without any of the above concerns.
Leon H. Kircik MD
Indiana University School of Medicine, Indianapolis, IN
Icahn School of Medicine at Mount Sinai, New York, NY
Physicians Skin Care, PLLC, Louisville, KY
Indiana University School of Medicine, Indianapolis, IN
Icahn School of Medicine at Mount Sinai, New York, NY
Physicians Skin Care, PLLC, Louisville, KY
Disclosures
Dr. Kircik has received compensation from the Journal of Drugs in Dermatology for his editorial
support.
References
- Leon H. Kircik MD, Joseph B. Bikowski MD, David E. Cohen MPH MD, Zoe Diana Draelos MD, Adelaide Hebert MD. Vehicles Matter. Supplement to Practical Dermatology. 2010;(12-14). http://bmctoday.net/vehiclesmatter/pdfs/0310.pdf Accessed May 19 2014.
- Cloderm [package insert]. Bridgewater, New Jersey: Promius Pharma, LLC; 2011.
